Therapeutic Solutions International Inc (TSOI)

[rrao11]

And don’t forget, $tsoi has the right people working there as well! Dr. Franco Marincola, being one of then. He has been with $tsoi since 2015 and knows $tsoi products inside out!

Oceanside, CA -- October 21, 2015 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today that Francesco M Marincola, MD, FACS, has been appointed to our Scientific Advisory Board.

Dr. Marincola previously held the position of Chief of the Infectious Disease and Immunogenetics Section (IDIS) and Tenured Senior Investigator at the U.S. National Institutes of Health (NIH). He was also Director of the Immunogenetics Program, Department of Transfusion Medicine, Director of the Federation of Clinical Immunology Societies (FOCIS) Center for Excellence and Co-Director of the Trans-NIH Center for Human Immunology.

Dr. Marincola received his MD summa cum laude from the University of Milan and his surgery training from Stanford University. Dr. Marincola is the second most cited scientist in the field of melanoma during the last ten years, with 55 papers cited 3,704 times to date. His research interest is primarily translational and focuses on the development of strategies for the dynamic study of patients response to therapies. His approach has deepened understanding of the mechanisms leading to rejection of tumors, allograft, graft versus host disease and leading to the development of autoimmunity.

With the appointment of Dr. Marincola to our Scientific Advisory Board who now joins Dr. Michael G. Agadjanyan, Dr. Santosh Kesari, and Dr. Harry Lander, we truly have a world class team of scientists to identify and discuss significant emerging regulatory, research and scientific issues and trends and competitive activity, including their potential impacts on any Company programs, plans, or policies relating to its development programs and research activities said Timothy Dixon, President and CEO of Therapeutic Solutions.